000118818 001__ 118818
000118818 005__ 20240319081006.0
000118818 0247_ $$2doi$$a10.1016/j.biopha.2022.113364
000118818 0248_ $$2sideral$$a130017
000118818 037__ $$aART-2022-130017
000118818 041__ $$aeng
000118818 100__ $$aButnariu, M.
000118818 245__ $$aThe effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies
000118818 260__ $$c2022
000118818 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118818 5203_ $$aThymoquinone (TQ) is a secondary metabolite found in abundance in very few plant species including Nigella sativa L., Monarda fistulosa L., Thymus vulgaris L. and Satureja montana L. Preclinical pharmacological studies have shown that TQ has many biological activities, such as anti-inflammatory, antioxidant and anticancer. Both in vivo and in vitro experiments have shown that TQ acts as an antitumor agent by altering cell cycle progression, inhibiting cell proliferation, stimulating apoptosis, inhibiting angiogenesis, reducing metastasis and affecting autophagy. In this comprehensive study, the evidence on the pharmacological potential of TQ on pancreatic cancer is reviewed. The positive results of preclinical studies support the view that TQ can be considered as an additional therapeutic agent against pancreatic cancer. The possibilities of success for this compound in human medicine should be further explored through clinical trials. © 2022 The Authors
000118818 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000118818 590__ $$a7.5$$b2022
000118818 592__ $$a1.366$$b2022
000118818 591__ $$aPHARMACOLOGY & PHARMACY$$b22 / 278 = 0.079$$c2022$$dQ1$$eT1
000118818 593__ $$aPharmacology$$c2022$$dQ1
000118818 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b27 / 136 = 0.199$$c2022$$dQ1$$eT1
000118818 593__ $$aMedicine (miscellaneous)$$c2022$$dQ1
000118818 594__ $$a12.6$$b2022
000118818 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118818 700__ $$aQuispe, C.
000118818 700__ $$aHerrera-Bravo, J.
000118818 700__ $$aHelon, P.
000118818 700__ $$aKukula-Koch, W.
000118818 700__ $$0(orcid)0000-0001-6969-1055$$aLópez Ramos, V.
000118818 700__ $$aLes, F.
000118818 700__ $$aVergara, C. V.
000118818 700__ $$aAlarcón-Zapata, P.
000118818 700__ $$aAlarcón-Zapata, B.
000118818 700__ $$aMartorell, M.
000118818 700__ $$aPentea, M.
000118818 700__ $$aDragunescu, A. A.
000118818 700__ $$aSamfira, I.
000118818 700__ $$aYessimsiitova, Z.
000118818 700__ $$aDastan, S. D.
000118818 700__ $$aCastillo, C. M. S.
000118818 700__ $$aRoberts, T. H.
000118818 700__ $$aSharifi-Rad, J.
000118818 700__ $$aKoch, W.
000118818 700__ $$aCho, W. C.
000118818 773__ $$g153 (2022), 113364 [10 pp]$$pBiomed. pharmacother.$$tBIOMEDICINE & PHARMACOTHERAPY$$x0753-3322
000118818 8564_ $$s2210368$$uhttps://zaguan.unizar.es/record/118818/files/texto_completo.pdf$$yVersión publicada
000118818 8564_ $$s2623158$$uhttps://zaguan.unizar.es/record/118818/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118818 909CO $$ooai:zaguan.unizar.es:118818$$particulos$$pdriver
000118818 951__ $$a2024-03-18-14:40:53
000118818 980__ $$aARTICLE